The use of a neonatal mouse model to study respiratory syncytial virus infections

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 12, 2010, Pages 1371-1380

  Cormier, Stephania A ^a   You, Dahui ^b   Honnegowda, Srinivasa ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

cotton rat; human; infant; mouse; neonate; respiratory syncytial virus

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

AIRWAY OBSTRUCTION; ANTIGEN PRESENTING CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COTTON RAT; COUGHING; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; FEVER; HUMAN; IMMUNE RESPONSE; LOEFFLER PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; LUNG LAVAGE; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RHINORRHEA; SNEEZING; TH2 CELL; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS REPLICATION; WHEEZING;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; HUMANS; INFANT; MICE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; SIGMODONTINAE;

EID: 78650207448     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.125     Document Type: Review

References (95)

1. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an ana lysis of national databases. Pharmacoeconomics 22(5), 275-284 (2004).
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140(6), 543-546 (1986).
3. Boeck KD. Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Monaldi Arch. Chest Dis. 51(3), 210-213 (1996).
4. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med. 300(10), 530-534 (1979).
5. Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360(6), 588-598 (2009).
6. Stang P, Brandenburg N, Carter B. The economic burden of respiratory syncytial virus-associated bronchiolitis hospitalizations. Arch. Ped. Adolesc. Med. 155(1), 95-96 (2001).
7. Fleming DM, Elliot AJ, Cross K W. Morbidity profles of patients consulting during infuenza and respiratory syncytial virus active periods. Epidemiol. Infect. 135(7), 1099-1108 (2007).
8. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am. J. Hyg. 66(3), 281-290 (1957).
9. Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr. Probl. Pediatr. 23(2), 50-79 (1993).
10. Bont L, Versteegh J, Swelsen WT et al. Natural reinfection with respiratory syncytial virus does not boost virus-specifc T-cell immunity. Pediatr. Res. 52(3), 363-367 (2002).
11. DeVincenzo J. Pre-emptive ribavirin for 'RSV in BMT. Bone Marrow Transplant. 26(1), 113-114 (2000).
12. Kimpen JL, Schaad UB. Treatment of respiratory syncytial virus bronchiolitis: 1995 poll of members of the European Society for Paediatric Infectious Diseases. Pediatr. Infect. Dis. J. 16(5), 479-481 (1997).
13. Respiratory Syncytial Virus. Red Book. American Academy of Pediatrics. 2009(1), 560-569 (2009).
14. Wu P, Dupont WD, Griffn MR et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am. J. Respir. Crit. Care Med. 178(11), 1123-1129 (2008).
15. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol. 20(1), 108-119 (2007).
16. Openshaw PJ. Antiviral immune responses and lung infammation after respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2(2), 121-125 (2005).
17. Sung RY, Hui SH, Wong CK, Lam CW, Yin J. A comparison of cytokine responses in respiratory syncytial virus and infuenza A infections in infants. Eur. J. Pediatr. 160(2), 117-122 (2001).
18. Mobbs KJ, Smyth RL, O'Hea U et al. Cytokines in severe respiratory syncytial virus bronchiolitis. Pediatr. Pulmonol. 33(6), 449-452 (2002).
19. Lee FE, Walsh EE, Falsey AR et al. Human infant respiratory syncytial virus (RSV)-specifc type 1 and 2 cytokine responses ex vivo during primary RSV infection. J. Infect. Dis. 195(12), 1779-1788 (2007).
20. Welliver TP, Garofalo RP, Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and infuenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis. 195(8), 1126-1136 (2007).
21. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identifcation of a previously unknown antigen-specifc regulatory T cell and its mechanism of suppression. Nat. Med. 6(7), 782-789 (2000).
22. Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS. NK T cells contribute to expansion of CD8+ T cells and amplifcation of antiviral immune responses to respiratory syncytial virus. J. Virol. 76(9), 4294-4303 (2002).
23. Openshaw PJ. Pulmonary epithelial T cells induced by viral infection express T cell receptors a/b. Eur. J. Immunol. 21(3), 803-806 (1991).
24. Openshaw PJ. Flow cytometric ana lysis of pulmonary lymphocytes from mice infected with respiratory syncytial virus. Clin. Exp. Immunol. 75(2), 324-328 (1989).
25. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26(2), 153-162 (1988).
26. Openshaw PJ. Potential mechanisms causing delayed effects of respiratory syncytial virus infection. Am. J. Respir. Crit. Care Med. 163(3 Pt 2), S10-S13 (2001).
27. Openshaw PJ. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am. J. Respir. Crit. Care Med. 152(4 Pt 2), S59-S62 (1995).
28. Boelen A, Andeweg A, Kwakkel J et al. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profle in RSV-challenged mice. Vaccine 19(7-8), 982-991 (2000).
29. van Schaik SM, Obot N, Enhorning G et al. Role of interferon g in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J. Med. Virol. 62(2), 257-266 (2000).
30. Schwarze J, Cieslewicz G, Joetham A et al. CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J. Immunol. 162(7), 4207-4211 (1999). (Pubitemid 29314808)
31. Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89(4), 422-434 (1969).
32. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89(4), 405-421 (1969).
33. Chin J, Magoffn RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfuenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89(4), 449-463 (1969).
34. Connors M, Kulkarni AB, Firestone CY et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol. 66(12), 7444-7451 (1992).
35. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary infammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70(5), 2852-2860 (1996).
36. Moore E, Barber J, Tripp R. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol. J. 5(1), 116 (2008).
37. Clyde WA Jr. Experimental models for study of common respiratory viruses. Environ. Health Perspect. 35, 107-112 (1980).
38. Piazza FM, Johnson SA, Darnell ME et al. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection. J. Virol. 67(3), 1503-1510 (1993).
39. Wyde PR, Ambrose MW, Meyerson LR, Gilbert BE. The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfuenza type 3 viruses in cotton rats. Antiviral Res. 20(2), 145-154 (1993).
40. Prince GA, Prieels JP, Slaoui M, Porter DD. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab. Invest. 79(11), 1385-1392 (1999).
41. Prince GA, Jenson AB, Hemming VG et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J. Virol. 57(3), 721-728 (1986).
42. Boukhvalova MS, Prince GA, Soroush L et al. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 24(23), 5027-5035 (2006).
43. Meissner HC, Welliver RC, Chartrand SA et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr. Infect. Dis. J. 18(3), 223-231 (1999).
44. Ottolini MG, Porter DD, Hemming VG et al. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant. 24(1), 41-45 (1999).
45. Prince GA, Mathews A, Curtis SJ, Porter DD. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. 182(5), 1326-1330 (2000).
46. Sami IR, Piazza FM, Johnson SA et al. Systemic immunoprophylaxis of nasal respiratory syncytial virus infection in cotton rats. J. Infect. Dis. 171(2), 440-443 (1995).
47. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am. J. Pathol. 93(3), 771-791 (1978).
48. Culley FJ, Pollott J, Openshaw PJ. Age at frst viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J. Exp. Med. 196(10), 1381-1386 (2002).
49. Dakhama A, Park J W, Taube C et al. The enhancement or prevention of airway hyper responsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at frst infection and IL-13 production. J. Immunol. 175(3), 1876-1883 (2005).
50. Ripple M, You D, Giaimo J et al. Immunomodulation with IL-4Ra antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. J. Immunol. 185, 4804-4811 (2010).
51. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4(7), 553-564 (2004).
52. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 17, 399-433 (1999).
53. Sun CM, Fiette L, Tanguy M, Leclerc C, Lo-Man R. Ontogeny and innate properties of neonatal dendritic cells. Blood 102(2), 585-591 (2003).
54. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffn MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J. Pediatr. 137(6), 865-870 (2000).
55. Forster J, Streckert HJ, Werchau H. The humoral immune response of children and infants to an RSV infection: its maturation and association with illness. Klin. Padiatr. 207(6), 313-316 (1995).
56. Wilczynski J, Lukasik B, Torbicka E, Tranda I, Brzozowska-Binda A. The immune response of small children by antibodies of different classes to respiratory syncytial virus (RSV) proteins. Acta Microbiol. Pol. 43(3-4), 369-379 (1994).
57. Sims DG, Downham MA, Gardner PS, Webb JK, Weightman D. Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy. Br. Med. J. 1(6104), 11-14 (1978).
58. Pullan CR, Hey EN. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. Br. Med. J. (Clin. Res. Ed.) 284(6330), 1665-1669 (1982).
59. McConnochie KM, Roghmann KJ. Bronchiolitis as a possible cause of wheezing in childhood: new evidence. Pediatrics 74(1), 1-10 (1984).
60. Murray M, Webb MS, O'Callaghan C, Swarbrick AS, Milner AD. Respiratory status and allergy after bronchiolitis. Arch. Dis. Child. 67(4), 482-487 (1992).
61. Stein RT, Sherrill D, Morgan WJ et al Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354(9178), 541-545 (1999).
62. Sigurs N, Gustafsson PM, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 171(2), 137-141 (2005).
63. Korppi M, Halonen P, Kleemola M, Launiala K. Viral fndings in children under the age of two years with expiratory diffculties. Acta Paediatr. Scand. 75(3), 457-464 (1986).
64. Piippo-Savolainen E, Remes S, Kannisto S, Korhonen K, Korppi M. Asthma and lung function 20 years after wheezing in infancy: results from a prospective follow-up study. Arch. Pediatr. Adolesc. Med. 158(11), 1070-1076 (2004).
65. Sigurs N, Aljassim F, Kjellman B et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the frst year of life. Thorax DOI: 10.1136/ thx.2009.121582 (2010) (Epub ahead of print).
66. Becnel D, You D, Erskin J, Dimina DM, Cormier SA. A role for airway remodeling during respiratory syncytial virus infection. Respir. Res. 6(1), 122 (2005).
67. You D, Becnel D, Wang K et al. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respir. Res. 7, 107 (2006).
68. Dakhama A, Lee YM, Ohnishi H et al. Virus-specifc IgE enhances airway responsiveness on reinfection with respiratory syncytial virus in newborn mice. J. Allergy Clin. Immunol. 123(1), 138-145.e5 (2009).
69. Choi EH, Lee HJ, Yoo T, Chanock SJ. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J. Infect. Dis. 186(9), 1207-1211 (2002).
70. Puthothu B, Krueger M, Forster J, Heinzmann A. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J. Infect. Dis. 193(3), 438-441 (2006).
71. Hoebee B, Rietveld E, Bont L et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor a polymorphisms. J. Infect. Dis. 187(1), 2-11 (2003).
72. Li L, Lee HH, Bell JJ et al. IL-4 utilizes an alternative receptor to drive apoptosis of Th1 cells and skews neonatal immunity toward Th2. Immunity 20(4), 429-440 (2004).
73. Lee HH, Hoeman CM, Hardaway JC et al. Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J. Exp. Med. 205(10), 2269-2280 (2008).
74. Dakhama A, Park JW, Taube C et al. The role of virus-specifc Immunoglobulin E in airway hyper responsiveness. Am. J. Respir. Crit. Care Med. 170(9), 952-959 (2004).
75. Reed JL, Welliver TP, Sims GP et al. Innate immune signals modulate antiviral and polyreactive antibody responses during severe respiratory syncytial virus infection. J. Infect. Dis. 199(8), 1128-1138 (2009).
76. Williams JV, Weitkamp JH, Blum DL, LaFleur BJ, Crowe JE Jr. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. Mol. Immunol. 47(2-3), 407-414 (2009).
77. Tripp RA, Hou S, Etchart N et al. CD4+ T cell frequencies and Th1/Th2 cytokine patterns expressed in the acute and memory response to respiratory syncytial virus I-ed-restricted peptides. Cell. Immunol. 207(1), 59-71 (2001).
78. Larranaga CL, Ampuero SL, Luchsinger VF et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr. Infect. Dis. J. 28(10), 867-873 (2009).
79. Bendelja K, Gagro A, Bace A et al. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine fow cytometry. Clin. Exp. Immunol. 121(2), 332-338 (2000).
80. Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J. Virol. 82(8), 4115-4124 (2008).
81. Heidema J, Lukens MV, van Maren WW et al. CD8+ T cell responses in bronchoalveolar lavage fuid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J. Immunol. 179(12), 8410-8417 (2007).
82. Lukens MV, van de Pol AC, Coenjaerts FE et al. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J. Virol. 84(5), 2374-2383 (2010).
83. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J. Exp. Med. 203(5), 1153-1159 (2006).
84. Gill MA, Palucka AK, Barton T et al. Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J. Infect. Dis. 191(7), 1105-1115 (2005).
85. Everard ML, Swarbrick A, Wrightham M et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch. Dis. Child. 71(5), 428-432 (1994).
86. Hussell T, Openshaw PJ. Intracellular IFN-g expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J. Gen. Virol. 79(Pt 11), 2593-2601 (1998).
87. Mejias A, Chavez-Bueno S, Raynor MB et al. Motavizumab, a neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibody signifcantly modifes the local and systemic cytokine responses induced by RSV in the mouse model. Virol. J. 4, 109 (2007).
88. Lindgren C, Grogaard J. Refex apnoea response and infammatory mediators in infants with respiratory tract infection. Acta Paediatr. 85(7), 798-803 (1996).
89. Hayes PJ, Scott R, Wheeler J. In vivo production of tumour necrosis factor-a and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus. J. Med. Virol. 42(4), 323-329 (1994).
90. McNamara PS, Flanagan BF, Selby AM, Hart CA, Smyth RL. Pro- and anti-infammatory responses in respiratory syncytial virus bronchiolitis. Eur. Respir. J. 23(1), 106-112 (2004).
91. Matsuda K, Tsutsumi H, Okamoto Y, Chiba C. Development of interleukin 6 and tumor necrosis factor a activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus. Clin. Diagn. Lab. Immunol. 2(3), 322-324 (1995).
92. Roman M, Calhoun WJ, Hinton KL et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am. J. Respir. Crit. Care Med. 156(1), 190-195 (1997).
93. Guerrero-Plata A, Casola A, Garofalo R P. Human metapneumovirus induces a profle of lung cytokines distinct from that of respiratory syncytial virus. J. Virol. 79(23), 14992-14997 (2005).
94. Bermejo-Martin JF, Tenorio A, Ortiz de Lejarazu R et al. Similar cytokine profles in response to infection with respiratory syncytial virus type a and type B in the upper respiratory tract in infants. Intervirology 51(2), 112-115 (2008).
95. Rose S, Lichtenheld M, Foote MR, Adkins B. Murine neonatal CD4+ cells are poised for rapid Th2 effector-like function. J. Immunol. 178(5), 2667-2678 (2007).